Highest-materiality recent filing
SkinHealth Systems agrees to $18M securities class action settlement; insurer pays $15M
Company will pay $3M of $18M total; remaining $15M from insurers to settle Alghazwi v. The Beauty Health Company.
SkinHealth receives Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq notice on May 8, 2026; closing bid price below $1.00 for 30 consecutive business days through May 7.
SkinHealth Q1 revenue $64.9M, adjusted EBITDA $8.5M; cuts FY revenue outlook
Net sales $64.9M (-6.8% YoY); net loss improved to ($6.6M) from ($10.1M).
Beauty Health renames to SkinHealth Systems; appoints three new independent directors
Company rebranded to SkinHealth Systems Inc. effective Apr 22, 2026; ticker SKIN unchanged.
BeautyHealth Q4 net loss narrows to $8.1M; adjusted EBITDA margin 18.3%
Net sales Q4 $82.4M (down 1% YoY); full year $300.8M (down 10% YoY).
BeautyHealth Q3 2025 revenue $70.7M down 10% YoY; Adj EBITDA $8.9M beats guidance
Net sales of $70.7M vs $78.8M YoY; net loss improved to $11.0M from $18.3M.
Beauty Health Company CEO Marla Beck Terminated Without Cause, Enters Separation Agreement
Marla Beck terminated as CEO, President, and director effective September 30, 2025, without cause and with no disagreement on Company matters.
Beauty Health names Pedro Malha as CEO effective Oct 1; Marla Beck steps down
Pedro Malha appointed President and CEO effective October 1, 2025; replaces Marla Beck who steps down Sept 30, remains advisor through Dec 31.
Beauty Health beats Q2, raises FY2025 forecast; revenue $78.2M, adj. EBITDA $13.9M
Q2 net sales $78.2M (down 13.7% YoY but beat expectations); net income $19.7M vs $0.2M.
Beauty Health issues $250M 7.95% convertible notes due 2028; conversion price ~$2.86
$250M principal amount of 7.95% Convertible Senior Secured Notes due Nov 15, 2028 issued on May 27, 2025.
Exchanges ~$413.2M aggregate principal of existing 1.25% convertible notes due 2026 for $250M new 7.95% convertible senior secured notes due 2028.
BeautyHealth Q1 revenue $69.6M (-14% YoY); adjusted EBITDA $7.3M vs $0.4M
Net sales $69.6M down from $81.4M; delivery systems $20.2M (-43.6%), consumables $49.4M (+8.3%).
BeautyHealth Q4 net sales $83.5M; adjusted EBITDA $9M, exceeds guidance high end
Q4 net sales $83.5M, full year $334.3M; adjusted EBITDA $9.0M (10.8% margin), exceeding guidance.
BeautyHealth Q3 net sales $78.8M (-19% YoY); adj. EBITDA $8.1M, revenue guidance cut, EBITDA raised
Q3 net sales $78.8M, down 19.1% YoY; delivery systems sales fell 46% to $27.6M, consumables up 10% to $51.2M.
BeautyHealth Q2 net sales down 23% YoY to $90.6M; revises full-year guidance
Net sales $90.6M, down 22.9% YoY; equipment sales fell while consumables grew 6.7%.
BeautyHealth Q1 net sales $81.4M, -5.7% YoY; net loss narrows to $0.7M
Delivery systems net sales $35.8M (down 21% from $45.4M); consumables $45.6M (up from $40.9M).
COO Brad Hauser mutually terminated without cause effective April 9, 2024; remains in advisory role through June 30, 2024.
Beauty Health discloses SEC subpoena; finalizes CEO Marla Beck employment terms
SEC's Enforcement Division issued subpoena in formal investigation; company cooperating, cannot predict scope or outcome.
Beauty Health appoints Marla Beck as permanent CEO; she had been interim since Nov 2023
Marla Beck named permanent President and CEO effective March 12, 2024.
BeautyHealth Q4 net sales $96.8M (-1.3% YoY); full year net loss $100.1M
Full year net sales $398.0M, up 8.8% YoY; Q4 net sales $96.8M, down 1.3% YoY.
CEO Andrew Stanleick terminated without cause effective Nov 19, 2023; signed Separation Letter on Dec 8, 2023.
Beauty Health CEO Andrew Stanleick departs; director Marla Beck named interim CEO
Andrew Stanleick steps down as CEO and board member effective Nov 19, 2023; will advise through Dec 31, 2023.
BeautyHealth reports Q3 net loss of $73.8M, revises FY2023 guidance lower
Net sales $97.4M (+10% YoY) but gross loss of $12.6M vs $61.4M profit a year ago; $63.1M restructuring charge for Syndeo device upgrades.
BeautyHealth launches cost-cutting program targeting $35M+ annual savings, $100M buyback
Phase 1 expected to generate >$20M annualized cost savings in Q1 2024; Phase 2 >$15M in Q2 2024.
Beauty Health names Michael Monahan CFO, replacing Liyuan Woo effective Aug 10, 2023
Michael Monahan appointed CFO effective August 10, 2023; Liyuan Woo steps down, stays as advisor until September 1.
BeautyHealth Q2 net sales $117.5M (+13% YoY); net income $3.4M; reaffirms FY guidance
Net sales $117.5M (+13% YoY); net income $3.4M; adjusted EBITDA margin 15.1%.
BeautyHealth Q1 net sales $86.3M (+14% YoY), net loss $22.3M, raises FY23 guidance
Net sales $86.3M (+14% YoY); consumables +21% YoY led by Americas +34% and EMEA +35% ex-Russia.
BeautyHealth promotes Brad Hauser to COO with $1.4M in equity grants
Brad Hauser appointed COO effective April 19, 2023; previously Chief Product Officer since Jan 2023.
BeautyHealth acquires SkinStylus microneedling device for $16.3M in cash and stock
Total consideration of $16.3M: $14.99M cash (incl. up to $3.2M contingent payments) and $1.31M in SKIN stock.
BeautyHealth reports FY2022 net sales $365.9M (+41% YoY); guides FY2023 $450-470M
Full year net sales $365.9M (+41% YoY); Q4 net sales $98.1M (+26% YoY).
terminated Ronald Menezes’ employment as Chief Revenue Officer of the Company without cause, effective as of May 6, 2026.
On May 5, 2026, the Board of Directors of SkinHealth Systems Inc. (the “Company”) terminated Mr. Ronald Menezes' employment as Chief Revenue Officer of the Company without cause, effective as of May 5, 2026.
Due to this determination, the Board designated Mr. Menezes as an executive officer, as that term is defined in 17 C.F.R. § 240.3b-7 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), thus making Mr. Menezes an executive officer subject to Section 16 of the Exchange Act (a "Section 16 Officer").
On October 8, 2024, the Board of Directors of the Company terminated Daniel Watson’s employment as Chief Revenue Officer of the Company without cause, effective as of October 14, 2024 (the "Termination Date").
On October 8, 2024, the Board of Directors (the "Board") of The Beauty Health Company (the "Company") terminated Daniel Watson's employment as Chief Revenue Officer of the Company without cause, effective as of October 14, 2024.
On August 26, 2024, Dr. Julius Few notified the board of directors (the "Board") of The Beauty Health Company (the "Company") of his decision to resign as a director of the Company, effective immediately.
On April 8, 2024, the Company and Brad Hauser mutually agreed to terminate Mr. Hauser’s employment as Chief Operating Officer of the Company without cause, effective as of April 9, 2024
On April 8, 2024, The Beauty Health Company (the "Company") and Brad Hauser mutually agreed to terminate Mr. Hauser’s employment as Chief Operating Officer of the Company without cause, effective as of April 9, 2024.
the Company’s Board of Directors (the “Board”) had unanimously approved Marla Beck to be the Company’s President and Chief Executive Officer.
Mr. Stanleick’s termination from his position as Chief Executive Officer of the Company without cause
Andrew Stanleick, who will step down from the role of chief executive officer of the Company, effective as of November 19, 2023.
the Board of Directors (the “Board”) of The Beauty Health Company (the “Company”) appointed Marla Beck, age 53, as interim chief executive officer of the Company (the “Interim CEO”), for a 6-month term (the “Term”) effective November 20, 2023
Max materiality 0.90 · Median 0.62 · Most common event leadership